Lessons from neonatal β-cell epigenomic for diabetes prevention and treatment

Abderrahmani, Amar; Jacovetti, Cécile; Regazzi, Romano

doi:10.1016/j.tem.2022.03.002

Cited by 8 publications

(12 citation statements)

References 109 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2022, 33, 378−389. 1 The review underlines the new trends in the f ield of diabetes. It presents the hypothesis that the newborn is a groundbreaking model for understanding the key mechanisms responsible for pancreatic β-cell mass expansion and for insulin secretion, and for identifying the future antidiabetic medicines • Szunerits, S.; Melinte, S.; Barras…”

Section: ■ Key Referencesmentioning

confidence: 99%

“… Lessons from neonatal β-cell epigenomic for diabetes prevention and treatmentAbderrahmaniA.JacovettiC.RegazziR. Abderrahmani, A. Jacovetti, C. Regazzi, R. Trends Endocrinol Metab.202233378389 …”

Section: Key Referencesmentioning

confidence: 99%

“…T2D develops when β-cells fail to adapt their insulin production to insulin resistance (Figure 1b). 1 Although there are treatments that lower glycemia in the first years, none of the current treatments is able to achieve long-term glycemic control. Hyperglycemia promotes in addition the formation of pancreatic islet amyloid deposition and has become a pathological hallmark of T2D.…”

Section: ■ Introductionmentioning

confidence: 99%

“…Age, obesity, bad dietary habits, lack of physical activity, and gestational diabetes all are risk factors for insulin resistance (Figure a). T2D develops when β-cells fail to adapt their insulin production to insulin resistance (Figure b) . Although there are treatments that lower glycemia in the first years, none of the current treatments is able to achieve long-term glycemic control.…”

Section: Introductionmentioning

confidence: 99%

“…Although there are treatments that lower glycemia in the first years, none of the current treatments is able to achieve long-term glycemic control. Hyperglycemia promotes in addition the formation of pancreatic islet amyloid deposition and has become a pathological hallmark of T2D. , Developing efficient drugs that prevent amyloid formation and preserve β-cell functions are sought after, with a limited number of small therapeutic molecules currently being considered in clinical trials. , An increasing amount of work indicates the interest of nanomaterials for helping in the inhibition of β-cell loss via interaction with cytotoxic amyloid fibrils.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Nanoparticles and Nanocolloidal Carbon: Will They Be the Next Antidiabetic Class That Targets Fibrillation and Aggregation of Human Islet Amyloid Polypeptide in Type 2 Diabetes?

2022

Self Cite

View full text Add to dashboard Cite

Conspectus Nanotechnology is revolutionizing human medicine. Nanoparticles (NPs) are currently used for treating various cancers, for developing vaccines, and for imaging, and other promises offered by NPs might come true soon. Due to the interplay between NPs and proteins, there is more and more evidence supporting the role of NPs for treating amyloid-based diseases. NPs can induce some conformational changes of the adsorbed protein molecules via various molecular interactions, leading to inhibition of aggregation and fibrillation of several and different amyloid proteins. Though an in depth understanding of such interactions between NPs and amyloid structures is still lacking, the inhibition of protein aggregation by NPs represents a new generation of innovative and effective medicines to combat metabolic diseases such as type 2 diabetes (T2D). Here, we lay out advances made in the field of T2D notably for optimizing protein aggregation inhibition strategies. This Account covers discussions about the current understanding of β-cells, the insulin producing cells within the pancreas, under diabetic conditions, notably increased glucose and fatty acid levels, and the implication of these conditions on the formation of human islet amyloid polypeptide (hIAPP) amylin oligomers and aggregates. Owing to the great potential of carbon nanostructures to interfere with protein aggregation, an important part of this Account will be devoted to the state of the art of therapeutic options in the form of emerging nanomaterials-based amyloidosis inhibitors. Our group has recently made some substantial progress in this regard by investigating the impact of glucose and fatty acid concentrations on hIAPP aggregation and β-cell toxicity. Furthermore, the great potential of carbon nanocolloids in reversing hIAPP aggregation under diabetic conditions will be highlighted as the approach has been validated on β-cell cultures from rats. We hope that this Account will evoke new ideas and concepts in this regard. We give some lead references below on pancreatic β-cell aspects and carbon quantum dots for managing diabetics and nanomedicine related aspects, a topic of interest in our laboratory.

show abstract

Section: ■ Key Referencesmentioning

confidence: 99%

Section: Key Referencesmentioning

confidence: 99%

Section: ■ Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Nanoparticles and Nanocolloidal Carbon: Will They Be the Next Antidiabetic Class That Targets Fibrillation and Aggregation of Human Islet Amyloid Polypeptide in Type 2 Diabetes?

2022

Self Cite

View full text Add to dashboard Cite

show abstract

Islet autoimmunity in human type 1 diabetes: initiation and progression from the perspective of the beta cell

et al. 2023

View full text Add to dashboard Cite

Type 1 diabetes results from the poorly understood process of islet autoimmunity, which ultimately leads to the loss of functional pancreatic beta cells. Mounting evidence supports the notion that the activation and evolution of islet autoimmunity in genetically susceptible people is contingent upon early life exposures affecting the islets, especially beta cells. Here, we review some of the recent advances and studies that highlight the roles of these changes as well as antigen presentation and stress response pathways in beta cells in the onset and propagation of the autoimmune process in type 1 diabetes. Future progress in this area holds promise for advancing islet- and beta cell-directed therapies that could be implemented in the early stages of the disease and could be combined with immunotherapies. Graphical Abstract

show abstract

Transcriptomic profiling analysis of the effect of palmitic acid on 3D spheroids of β-like cells derived from induced pluripotent stem cells

Morisseau,

Tokito,

Lucas

et al. 2024

Gene

View full text Add to dashboard Cite

Lessons from neonatal β-cell epigenomic for diabetes prevention and treatment

Cited by 8 publications

References 109 publications

Nanoparticles and Nanocolloidal Carbon: Will They Be the Next Antidiabetic Class That Targets Fibrillation and Aggregation of Human Islet Amyloid Polypeptide in Type 2 Diabetes?

Nanoparticles and Nanocolloidal Carbon: Will They Be the Next Antidiabetic Class That Targets Fibrillation and Aggregation of Human Islet Amyloid Polypeptide in Type 2 Diabetes?

Islet autoimmunity in human type 1 diabetes: initiation and progression from the perspective of the beta cell

Transcriptomic profiling analysis of the effect of palmitic acid on 3D spheroids of β-like cells derived from induced pluripotent stem cells

Contact Info

Product

Resources

About